Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Name
nihms901248.pdf
Size
449.09 KB
Format
Adobe PDF
Checksum (MD5)
4693362c68835ba78be20a1ca98acfc6
Author(s)
Sayin, Volkan I.
Singh, Simranjit X.
LeBoeuf, Sarah E.
Karakousi, Triantafyllia R.
Martinez, Britney
Bronson, Roderick T.
Prigge, Justin R.
Schmidt, Edward E.
Thomas, Craig J.
Goparaju, Chandra
Date Issued
October 2017
Journal
Nature Medicine
Publisher
Nature Publishing Group
Citation
Romero, Rodrigo et al. “Keap1 Loss Promotes Kras-Driven Lung Cancer and Results in Dependence on Glutaminolysis.” Nature Medicine (October 2017): 1362–1368 © 2017 Nature America, Inc., part of Springer Nature
Version
Author's final manuscript
Abstract
Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors. Approximately 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (refs. 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response. The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis. Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression. We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice. Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacological inhibition of glutaminase. Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/NM.4407
